We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
76
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.51M 0.24%
+107,510
New +$6.4M
TPST icon
77
CALL
Tempest Therapeutics
TPST
$13.9M
$6.37M 0.23%
+1
New +$91.6K
LPCN icon
78
Lipocine
LPCN
$17.6M
$6.22M 0.23%
+42,647
New +$5.29M
LUMO
79
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$6.18M 0.23%
155
-11
-7% -$4.67K
ACHN
80
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$6.13M 0.22%
6,916
+1,477
+27% +$14K
ONCE
81
CALL
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$5.41M 0.2%
+898
New +$59.4K
NVAX icon
82
CALL
Novavax
NVAX
$1.21B
$5.24M 0.19%
235
– –
AMG icon
83
PUT
Affiliated Managers Group
AMG
$9.78B
$5.2M 0.19%
+238
New +$52.9K
BLCM
84
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$5.13M 0.19%
24,104
+952
+4% +$233K
SRPT icon
85
PUT
Sarepta Therapeutics
SRPT
$1.63B
$5.1M 0.19%
1,677
+698
+71% +$14.3K
TXMD icon
86
CALL
TherapeuticsMD
TXMD
$23.8M
$5.08M 0.19%
129
+59
+84% +$20.8K
ASXC
87
DELISTED
Asensus Surgical, Inc.
ASXC
$5.06M 0.18%
+129,677
New +$5.97M
VXZ
88
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$5.03M 0.18%
+112,500
New +$5.2M
BCRX icon
89
PUT
BioCryst Pharmaceuticals
BCRX
$2.48B
$4.96M 0.18%
3,319
+2,961
+827% +$33.7K
ACAD icon
90
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
$4.91M 0.18%
+1,173
New +$45.4K
DERM
91
DELISTED
Dermira, Inc.
DERM
$4.86M 0.18%
276,994
-108,191
-28% -$1.67M
ONCS
92
DELISTED
OncoSec Medical Incorporated
ONCS
$4.86M 0.18%
+3,490
New +$5.23M
ENDP
93
CALL
DELISTED
Endo International plc
ENDP
$4.79M 0.17%
601
– –
VXZ
94
CALL
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$4.77M 0.17%
+1,068
New +$49.3K
MNK
95
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$4.77M 0.17%
40,539
+33,259
+457% +$4.1M
HCA icon
96
CALL
HCA Healthcare
HCA
$92.8B
$4.75M 0.17%
524
-413
-44% -$33.1K
ALNY icon
97
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
$4.74M 0.17%
+395
New +$47.2K
ONCE
98
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$4.57M 0.17%
+759
New +$50.2K
APC
99
CALL
DELISTED
Anadarko Petroleum
APC
$4.53M 0.17%
+580
New +$50.2K
CYH icon
100
PUT
Community Health Systems
CYH
$393M
$4.45M 0.16%
855
-2,391
-74% -$107K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.